outcomes of rTM treatment for each grade of SOS according to this concept, including mild SOS in four patients, moderate SOS in two patients and severe SOS in three patients, all of whom received allogeneic HSCT at our institution between June 2010 and October 2015.
Patient characteristics and HSCT procedures are summarized in Table 1 . For SOS prophylaxis, all nine patients received a continuous infusion of 75-unit/kg/day of low-molecular-weight heparin from the day the preparative conditioning regimen was started. The possibility of other etiologies such as acute GvHD, thrombotic microangiopathy (TMA), engraftment syndrome, infections, drug-induced cholestasis and volume overload was evaluated iteratively, with reference to clinical manifestations and the laboratory data of each patient. In all cases, these alternative diagnoses were ruled out. The characteristics of SOS and treatment outcomes are shown in Table 2 . Liver biopsy was not performed in any of the patients. All patients developed coagulation abnormalities and thrombocytopenia, including seven with transfusion-refractory thrombocytopenia, which indicated the presence of disseminated intravascular coagulopathy (DIC) accompanied by SOS. On the basis of these manifestations, the patients were considered candidates for rTM therapy. All patients received rTM (380 U/kg/day), and the median time between the onset of SOS and the initiation of rTM was 2 days (range, 1-8 days). For all nine patients, no agent was used for the treatment of SOS before rTM administration.
In the four patients with mild SOS, the signs of improvement of SOS-related symptoms appeared consistently at a median of 2.5 days (range, 1-3 days) after initiation of rTM therapy. Thereafter, SOS was resolved in all patients. On the other hand, the two patients with moderate SOS required administration of prednisone (PSL) in addition to rTM therapy to improve the SOS symptoms. Patient 5 received rTM therapy from day 19 after HSCT, Abbreviations: ALCL = anaplastic large cell lymphoma; ATG = antithymocyte globulin; BM = bone marrow; BU = busulfan; CDA = congenital dyserythropoietic anemia; CY = cyclophosphamide; F = female; Flu = fludarabine; GO = gemtuzumab ozogamicin; HSCT = hematopoietic stem cell transplantation; JMML = juvenile myelomonocytic leukemia; LMWH = low-molecular-weight heparin; M = male; Mel = melphalan; PB = peripheral blood; RD = related donor; SOS = sinusoidal obstructive syndrome; sMTX = short-term methotrexate; Tac = tacrolimus; UCB = unrelated cord blood; UD = unrelated donor; VP16 = etoposide. but her body weight and serum creatinine level continued to increase. Additional treatment with 2 mg/kg/day of PSL was started 4 days after rTM initiation, with subsequent improvement in her body weight and serum creatinine level. Patient 6 had liver dysfunction with a serum transaminase level of 45 times the normal level and received rTM therapy from day 25 after HSCT. On the following day, she developed hypoxia that required supplemental oxygen support. She was found to have a pleural effusion and, therefore, was administered 1 mg/kg/day of PSL. Thereafter, serum transaminase level began to decrease and abdominal pain was resolved. Both patients achieved resolution of moderate SOS. By contrast, all three patients with severe SOS showed no response to rTM therapy and additional PSL administration. Patient 7 developed a right upper quadrant pain on day 13 after HSCT. The total serum bilirubin level had increased gradually, reaching 2 mg/dL on day 18, when the diagnosis of SOS was made. Administration of rTM was started on day 21, but his condition continued to deteriorate. Another two patients (patients 8 and 9) developed SOS on days − 1 and 8 after HSCT, respectively, and both progressively worsened despite immediate administration of rTM and PSL after the diagnosis of SOS. All three patients died of SOS. In one of these patients, rTM therapy was discontinued 6 days after initiation because of upper gastrointestinal bleeding, although the association with the use of rTM was uncertain. rTM is a new, costly drug approved for treatment of DIC in Japan. It is not yet available or approved for this indication in other countries. rTM inactivates intravascular coagulation by binding to thrombin, and the thrombin-rTM complex activates protein C, consequently leading to inhibition of further thrombin formation. 11 rTM increases antithrombin III level and decreases plasminogen activator inhibitor 1 level in patients with DIC, suggesting that rTM has a protective effect against injury on endothelial cells. rTM also exhibits anti-inflammatory activity through several different mechanisms, 12, 13 suggesting that rTM may have a protective effect against endothelial damage by inhibiting amplification of the systemic inflammatory response caused by increased circulation of high-mobility group B1 protein.
Recently, in addition to the benefit for treatment of SOS, [5] [6] [7] successful treatment result from rTM therapy for TMA after HSCT was reported.
14 Furthermore, a prospective study showed the potential use of rTM as prophylaxis for acute GvHD and SOS. 15 These studies support the possible role of rTM in preventing endothelial damage.
On the basis of our limited experience, rTM therapy was clearly effective for patients with mild SOS, as has been reported previously. However, rTM was not effective as a single agent for patients with moderate SOS, who require additional PSL therapy. For patients with severe SOS, rTM combined with PSL could not resolve this life-threatening complication. The benefit of rTM with or without PSL was observed even in three patients who developed mild or moderate SOS relatively late after HSCT (patients 3, 4 and 6). For patients with mild SOS, rTM therapy might be feasible for preventing the progression to a more critical SOS, although the decision to initiate a therapeutic intervention is difficult because of the possibility of a spontaneous resolution. Several studies support early identification and treatment before disease progression. 4, 8 In contrast, our results suggest that rTM therapy is not necessarily effective for a more progressive SOS, which has already become a moderate or severe disease, mostly with organ dysfunctions. Development of a novel treatment strategy might be necessary for these patients. For moderate SOS, rTM combined with PSL could be a treatment of choice.
